Findings

What do systematic reviews say?

4 questions · 4 findings · 2 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 2 · 50%Low 0 · 0%Moderate 2 · 50%High 0 · 0%

Major bleeding · people with chronic kidney disease (predialysis (GFR 15 to 60 mL/min/1.73 m²), HD, PD, transplant recipients)

Antiplatelet agents probably leads to higher major bleeding compared with control (moderate certainty).

1 finding from 1 review

Antiplatelet agents for chronic kidney disease 2022 · Cochrane Headline outcomes only
RR 1.35 [1.1, 1.65]
29 studies · 16194 participants
Moderate

Major bleeding · people requiring treatment for acute DVT

1 finding from 1 review

Antiplatelet agents for the treatment of deep venous thrombosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 500 participants
Very low

Major bleeding · people requiring treatment for chronic DVT

Chronic DVT ‐ antiplatelet agents plus BMP showed no clear difference in major bleeding compared with BMP plus placebo (moderate certainty).

1 finding from 1 review

Antiplatelet agents for the treatment of deep venous thrombosis 2022 · Cochrane Headline outcomes only
RR 0.98 [0.29, 3.34]
1 study · 583 participants
Moderate

Major bleeding · people requiring treatment for chronic DVT

1 finding from 1 review

Antiplatelet agents for the treatment of deep venous thrombosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 224 participants
Very low